Stay Updated: Posts | Comments

  • 3rd October 2010 - By Joel Lord

    pharmafraud“The Pharmaceutical Industry is in the business of disease maintenance & symptom management. They are not in the business to cure Cancer, to cure Alzheimer’s, to cure heart disease, because if they were they would be in the business of putting themselves out of business; and that in fact doesn’t make sense. The Pharmaceutical Industry makes 5-6 times the amount of money of any of the other Fortune 500 companies in the United States of America. They are not going to easily or readily give up that income.

    The Pharmaceutical Industry doesn’t want to cure people. You need to understand specifically when we’re talking about psychiatric drugs, in particular, that these are drugs that encourage people to remain customers of the Pharmaceutical Industry. in fact you will be told, if you’re given a drug such as an anxiolytic, or antidepressant or an anti-psychotic drug that you may be on the drug for the rest of your life. And very frequently people find that they are on the drugs for a very long time, if not permanently, because they’re almost impossible to get off of. Some of them can have very serious withdrawal symptoms. Most of them can have very serious withdrawal symptoms if they’re stopped cold turkey. But some people even experience sever withdrawal symptoms when they try to titrate or they try to eliminate the drug little by little day after day.

    Fallacy2So it’s really important to understand the motivation behind all of the current maintenance drugs that are on the market; even drugs such as Cholesterol lowering Drugs; which lower cholesterol excessively while causing other disease states as a consequence. You’re never going to have anyone come to you and tell you that the drugs are always tried against a placebo (sugar pill) in clinical trials. In fact many drugs are found not to be more efficacious than the sugar pill.

    Case in point is the recent clinical trials that were released & the meta analysis that came out of the UK on anti-depressants, on the newer SSRI (selective Seratonin re-uptake inhibitors) – and what was found was that anti-depressants are no more effective than a placebo, no more effective than sugar pills; but yet there are more than 44 million people that have been taking these anti-depressants. And a large number of them, people that have mild to moderate depressive episodes. In fact they proved that the anti-depressants weren’t effective in anyone with the exception of some of the most severely depressed patients.” Gwen Olsen (former Pharmaceutical Representative)

    “Pharmaceutical Industry Sales-rep training to get the maximum results out of your presentation –

    How to profile physicians based on their personality types, so you would know how to be most influential with that doctor and get them to prescribe your drug:

    a. Analytical type: Approach him with a research study. People who like numbers, so provide them with that type of information.

    b. Amiable type : You can get them to do almost anything that you want them to do because they’re people pleasers who want to make you happy. You can lean on these people as opinion leaders if you want them to promote drugs ‘off label’ for you with other practices, or with other physicians.

    c. Driver type: Doctors in charge. You have to take the back seat and let them think they’re leading the conversation; that you’re not teaching them anything, you’re just talking to them.” Gwen Olsen

    selective serotonin reuptake inhibitors.Selective Serotonin Re-uptake Inhibitor (ie Paxil) type anti-depressant adverse reactions include: ‘Suicidality and violence through means other than akathisia, including drug-induced agitation, depression, and mania. Patients who were previously depressed can be pushed into states of agitated depression or manic-like reactions.’

    (1) The production of a stimulant continuum that often begins with lesser degrees of insomnia, nervousness, anxiety, hyperactivity & irritability, then progresses toward more severe agitation, aggression, varying degrees of mania. Mania or manic-like symptoms include disinhibition, grandiosity, sleep disturbances, and out-of-control aggressive behavior, including cycling into depression & suicidality.

    (2) The production of a combined state of stimulation and depression – an agitated depression – with a high risk of suicide and violence. Often the overall depression is markedly worsened.

    (3) The production of obsessive preoccupations with aggression against self or others, often accompanied by a worsening of any pre-existing depression.

    (4) The production of akathisia, an inner agitation or jitteriness that is usually (but not always) accompanied by an inability to stop moving. It is sometimes described as psychomotor agitation or restless leg syndrome. The state causes heightened irritability and frustration with aggression against self or others, and often a generally worsening of the mental condition.
    http://www.breggin.com/31-49.pdf

    How GlaxoSmithKline Suppressed Data on Paxil-Induced Akathisia: Implications for Suicidality and Violence, Peter R. Breggin, MD, Ithaca, New York (Ethical Human Psychology and Psychiatry, Volume 8, Number 2, Summer 2006) –

    ‘Akathisia is a drug-induced inner agitation or dysphoria that causes a person to feel compelled to move about. The painful feelings associated with akathisia have been compared to torture and often make people feel as if they are going “crazy.” People who suffer from akathisia often voice dramatic descriptions such as “electricity streaming through my veins,” “horrible jagged feelings inside my head” or “something pinching my nerves all over my body.” These vivid, desperate descriptions can be mistaken for delusions or hallucinations (American Psychiatric Assoc, 1994, 2000; Breggin, 1997).

    paxilWhen the FDA initially approved Paxil in December 29, 1992, it had already been reported that SSRI antidepressants tend to induce extremely high rates of akathisia. For example, Lipinski, Mallaya, Zimmerman, and Pope (1992) described five cases and, based on a review of the literature, they estimated that Prozac (fluoxetine) causes akathisia in 9.7%-25% of patients.

    Since the 1970s, studies of neuroleptic-induced akathisia have demonstrated that akathisia causes severe emotional disturbances, including aggression, suicidality, and a worsening of psychosis (van Putten, 1975; van Putten & Marder, 1987; Breggin, 1983, 1997). In the early 1990s, clinical reports began to link Prozac-induced akathisia to severe, acute, and obsessive suicidality (e.g., Rothschild & Locke, 1991; Teicher, Glod, & Gole, 1990).

    In 1994, the Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition (DSMIV, 1994, pp. 744-746) attempted to sum up the available clinical and research data concerning drug-induced akathisia. It stated, “Akathisia may be associated with dysphoria, irritability, aggression, or suicide attempts.” It also linked akathisia to “worsening of psychotic symptoms or behavioral dyscontrol.” The manual focused on neuroleptic-induced akathisia but made clear that the same problems are associated with SSRI antidepressantinduced akathisia: “Serotonin specific reuptake inhibitor antidepressant medications may produce akathisia that appears to be identical in phenomenology and treatment response to Neuroleptic-induced Acute Akathisia.”^

    Because it was already known that SSRI-induced akathisia causes suicidality, violence, and overall mental deterioration, it was beholden on GSK to conduct a careful analysis special Report Part U 93 of Paxil-induced akathisia. It was also beholden on the company to look for a link between Paxil-induced akathisia and mental or behavioral abnormalities. Instead, GSK went to extreme lengths to hide the fact that Paxil causes akathisia & that the some Paxil akathisia cases were associated with suicidality.

    SSRI antidepressants can cause suicidality and violence through means other than akathisia, including drug-induced agitation, depression, and mania. Patients who were previously depressed can be pushed into states of agitated depression or manic-like reactions (Breggin, 2003). The stimulating effects of SSRIs, from akathisia and agitation to mania, are responsible for causing some of the most severe mental and behavioral aberrations.

    Some progress has been made by the Food and Drug Administration (FDA) in warning about the risks associated with SSRI stimulation or activation (reviewed in Breggin, 2005). The agency now requires antidepressant labels to carry several warnings related to overstimulation and akathisia including the following –

    Clinical Worsening and Suicide Risk: Patients, their families and caregivers should be encouraged to be alert to the emergence of anxiety, agitation, panic attacks, insomnia, irritability, hostility, aggressiveness, impulsivity, akathisia (psychomotor restlessness), hypomania, mania, and other unusual changes in behavior, worsening of depression, and suicidal ideation, especially early during antidepressant treatment and when the dose is adjusted up or down. (FDA, 2005a, p. 2)

    The FDA also requires antidepressant labels to carry a black box warning about the increased risk of suicidality in children who take these drugs (FDA, 2005a). Although specific warning ahout the increased risk of suicidality in adults who take these antidepressants is not required, the FDA has issued a Puhlie Health Advisory ahout the potential danger in adults (FDA, 2005b). The data disclosed in this Special Report should lend scientific weight to the FDA’s concerns & encourage a specific lahel warning ahout the increased risk of suicidality in adults taking SSRI antidepressants such as Paxil.’

    ‘The following excerpts from my product liability report dated July 21, 2001, focus on akathisia. In addition to examining how GSK manipulated or suppressed data concerning akathisia, these findings confirm a link between Paxil-induced akathisia and suicidality. The data also confirm that these severe reactions can occur beginning with the first dose of the drug and that they often occur within the first few days of the initial exposure. My product liability report can be found in its entirety on my website, www.breggin.com. It covers numerous additional concerns about how GSK researched, developed, and marketed Paxil.

    GlaxoSmithKline fined $750 Million (tainted Drugs Paxil & Avandia) via whistleblower testimony –

    ‘GlaxoSmithKline Plc, the U.K.’s largest drugmaker, will pay $750 million to settle a U.S. whistleblower lawsuit over the sale of defective drugs. Glaxo was accused in court papers of selling tainted drugs under false pretenses. The medicines, made at a Glaxo plant in Cidra, Puerto Rico, were misidentified as a result of product mix-ups, according to papers filed in federal court in Boston. The affected drugs included the antidepressant Paxil CR and the diabetes treatment Avandamet. [Note that this is a combination drug that includes Avandia – ed].

    The settlement includes a criminal fine and forfeiture totaling $150 million and a $600 million civil settlement under the False Claims Act and related state claims, the Justice Department said in a statement. We will not tolerate corporate attempts to profit at the expense of the ill and needy in our society — or those who cut corners that result in potentially dangerous consequences to consumers,’ Carmen M. Ortiz, the U.S. Attorney in Boston, said at yesterday’s news conference.’
    http://hcrenewal.blogspot.com/2010/10/glaxosmithkline-subsidiary-pleads.html

    ‘The FDA, especially in the area of antidepressants, has long been seen by much of the scientific community as compromised by drug company influence and it is decreasingly recognized as a serious regulatory agency. In a 1991 FDA “blue ribbon” panel investigating the association between Prozac-type antidepressants & violence, five of the nine FDA panel doctors had ties to pharmaceutical corporations. The panel voted not to require these antidepressants to display a violence warning label. This  was aided by Paul Leber, director of the FDA’s Division of Neuropharma- cological Drug Products, who in the late 1990s left the FDA to direct a consulting firm that specializes in advising pharmaceutical companies that are attempting to gain FDA approval for new psychiatric drugs.

    The revolving door of employment between the FDA and Big Pharma resembles other governmental-industrial arrangements where regulatory favors routinely result in future industry income. In 2001 The Lancet, Great Britain’s respected medical journal, described the FDA as a “servant of industry.”

    Before approving a drug, the FDA does no research on that drug. Instead, the FDA evaluates studies handed to them by the pharmaceutical company that created the drug. Despite repeated evidence of untrustworthiness and outright fraud, the FDA continues to trust Big Pharma data.’
    http://brucelevine.net/zmag-behindpaxilscandals-levinepr0405.htm

    ‘Paxil Suicide Data Sealed in Company Files –
    I (Dr. Peter Breggin) recently published analyses of previously sealed GSK data on Paxil suicide in the peer-reviewed journal Ethical Human Psychology and Psychiatry. I combed the data out of GSK files during a several-day investigation of the company’s Paxil records. My original medical-legal report recently became unsealed and provided the basis for the published reports.

    The first report shows how GSK omitted some suicides and suicide attempts from their tables and from the data sent to the FDA. The second shows how the company hid data on Paxil-induced akathisia (psychomotor restlessness) and its relationship to suicidality. The third shows how the company hid the basic concept of activation or stimulation that recently became a central part of the newly mandated antidepressant labels. [Go to Breggin Selected Scientific Papers for Paxil Special Reports 1 through 3]

    The sealed Prozac data from Eli Lilly also came from my investigations of the company as a medical expert in product liability suits. BMJ (The British Medical Journal) recently obtained the sealed documents from an anonymous source and released them to the FDA and the U.S. Congress. The documents are contained in four Lilly PDFs that can be downloaded from my professional website [www.breggin.com].

    Lilly PDFs 1 to 3 show that the drug company knew in 1985 that patients taking Prozac had a 12 to1 increase in suicide attempts compared to placebo or to an older antidepressant. This original data and the analyses were never shown to the FDA until the BMJ recently forwarded them to the agency. The FDA has never responded. [Go to Lilly PDF 1] [Go to Lilly PDF 2] [Go to Lilly PDF 3]

    Lilly PDF 4 contains several studies. Most important, two in-house memoranda show that Eli Lilly was purposely hiding suicide attempts and suicide ideation by coding them under false categories, such as “depression” and “no drug effect” (pages 3 and 4 of Lilly PDF 4). Eli Lilly employee Claude Bouchy expressed shame about going along with this fraudulent practice: “I do not think I could explain to the BGA [the German regulatory agency], to a judge, to a reporter or even to my family why we would do this especially on the sensitive issue of suicide and suicide ideation.” [Go to Lilly PDF 4]

    The data used to evaluate antidepressant-induced suicidality in adults is not reliable. This is a fact the FDA has yet to face. The data has been pruned, culled and manipulated by the drug companies before being tabulated and released. The FDA must send investigators into the original drug company files to search and analyze the primary sources of data, much as I have done as a medical expert in product liability suits against drug companies. I will be happy to share my knowledge with FDA officials on how to conduct these searches and analyses.

    Kirsch, I. and Sapirstein, G. (1998). Listening to Prozac but hearing placebo: A meta-analysis of antidepressant medication. Prevention & Treatment, 1, Article 0002a, 16 pages, posted June 26, 1998. www.journals.apa.org.

    Breggin, P. (2006a). Court filing makes public my previously suppressed analysis of Paxil’s effects. Ethical Human Psychology and Psychiatry, 8, 77-84, 2006. Available on www.breggin.com.

    Breggin, P. (2006b). How GlaxoSmithKline suppressed data on Paxil-induced akathisia: Implications for suicide and violence. Ethical Human Psychology and Psychiatry, 8, 91-100.

    Breggin, P. (2006c) Drug company suppressed data on paroxetine-induced stimulation: Implications for violence and suicide. Ethical Human Psychology and Psychiatry, 8, 255-263.

    Lilly Documents, Folders 1-4 (2006). Dr. Breggin analyzes Eli Lilly Prozac-induced suicide and violence documents now in possession of the British Medical Journal (BMJ). www.breggin.com. Retrieved December 10, 2006.’
    http://www.huffingtonpost.com/dr-peter-breggin/the-big-suicide-loophole-_b_35990.html

    Systemic Drug Manufacturer cover-up of SSRI adverse effects on human behavior: Eli Lilly Clinical Trial data on Prozac (Fluoxetine) – “This person had no suicide ideation at onset of study. The patient drank a bottle of rum and then took ten fluoxetine (Prozac) capsules in divided doses over 2-hour intervals. Dr.___ and I agreed this was not a suicide attempt.” P.3
    http://www.breggin.com/elilillydocspart1.pdf

    Note: Parents out there who insist on forcing your precious child to take these behavior altering drugs, please reconsider. Many of them won’t make it back from the brink…and you will have lost that rarest of gifts, the free living life of your loved one. Think about it. VRM

    Gwen OlsenGwen Olsen: Pharma Not in Business of Health, Healing, Cures, Wellness
    http://www.youtube.com/watch?v=AazObF_pHSU&p=7190656F68589784&index=38&feature=BF

    Gwen Olsen: Ex-Pharmaceutical Rep. Speaks Out
    http://www.youtube.com/watch?v=KFbs8s3VI6M&p=7190656F68589784&playnext=1&index=33

    Ex Drug Rep Gwen Olsen on Manipulating Doctors
    http://www.youtube.com/watch?v=kOW8LNU2hFE&feature=related

    Dr John Rengen Virapen, former Drug Salesman for Eli Lily exposes big Pharma (Complete version/German gives way to English so be patient) – explosive material
    http://www.dailymotion.com/relevance/search/azk/video/x9289r_3-azk-dr-john-rengen-virapen-nebenw_news

    Eustace Mullins – Murder by Injection Interview(1993) – part 1 of 3
    http://www.youtube.com/watch?v=oVgGCm8aJBM&feature=PlayList&p=E8DCB206195707A6&index=10

    Eustace Mullins: The Rockefeller Medical Conspiracy
    http://www.youtube.com/watch?v=cNGvoCNhRlA&playnext_from=TL&videos=f8b_OWnepRo

    Pharma Insider reveals typical dirty tricks used to influence doctors & exploit Industry competitors –
    Part I: http://www.youtube.com/watch?v=oeavs_3SL2E
    part 2: http://www.youtube.com/watch?v=Wb_K49a2ERU&feature=related

    Related Articles:

    VRM Worldwide Autism Study
    http://vaccineresistancemovement.org/?page_id=5463

    VRM: The Problem With Vaccines Part 1
    http://vaccineresistancemovement.org/?p=488

    VRM: The Problem With Vaccines Part 2 – Synergistic Effect of Heavy Metal Toxicity On The Body
    http://vaccineresistancemovement.org/?p=6097

    VRM: Vaccine Clinic – A Concise Compendium To The Problem With Vaccines
    http://vaccineresistancemovement.org/?p=6278

    VRM: The Problem With Vaccines Part 3 – Synthetic Genomics & The Death Of Natural Immunity
    http://vaccineresistancemovement.org/?p=6880

    VRM: A Concise Compendium To The Problem With Vaccines Part 3 – Synthetic Genomics & The Death Of Natural Immunity
    http://vaccineresistancemovement.org/?p=7283

    VRM: The Problem With Vaccines Part 4 – Primary Aspects of Vaccine Toxicity Affecting Body
    http://vaccineresistancemovement.org/?p=8787

    VRM: The Problem With Vaccines Part 5A – Detoxification & Restoration of the Body
    http://vaccineresistancemovement.org/?p=8836

    VRM: The Problem With Vaccines Part 5B – Detoxification & Restoration of the Body
    http://vaccineresistancemovement.org/?p=8847

    VRM: Vaccine Ingredients
    http://vaccineresistancemovement.org/?p=979

    VRM: Family Charts Gradual Decline Of Daughter
    http://vaccineresistancemovement.org/?p=3156

    VRM: Autism – Steps To Take Toward Prevention
    http://vaccineresistancemovement.org/?p=3028

    VRM: Health Matters Part 1
    http://vaccineresistancemovement.org/?p=6719

    VRM: Health Matters Part 2
    http://vaccineresistancemovement.org/?p=6746%EF%BB%BF

    VRM: Alternative Cancer Cures That Work
    http://vaccineresistancemovement.org/?p=3729

    VRM: Pregnancy Tips
    http://vaccineresistancemovement.org/?p=3270

    VRM: The Vanishing Sperm Count
    http://vaccineresistancemovement.org/?p=4639

    VRM: Media Spin & Swine Flu Hysteria
    http://vaccineresistancemovement.org/?p=2347

    VRM: H1N1 Vaccine Surplus From 2009 Reveals Growing Distrust of Gov’t & WHO – Cost To Taxpayers Exceeds 2.5 Billion
    http://vaccineresistancemovement.org/?p=4969

    VRM: Flu Death Statistics – WHO & The Big Lie
    http://vaccineresistancemovement.org/?p=784

    VRM: Polio – United Nations & The Great Cull
    http://vaccineresistancemovement.org/?p=4916

    VRM : Vaccine Industry Deception, Propaganda & Media Collusion
    http://vaccineresistancemovement.org/?p=197

    VRM: Birth of Medical & Scientific Dictatorship – Future Scenarios
    http://vaccineresistancemovement.org/?p=997

    VRM: H1N1 Bio-weaponry Incorporated
    http://vaccineresistancemovement.org/?p=884

    VRM : Aids & The WHO Connection – Criminal Intent
    http://vaccineresistancemovement.org/?p=1749

    VRM: Morgellons Syndrome & Chemtrails
    http://vaccineresistancemovement.org/?p=839

    VRM : Council On Foreign Relations 10/16/09- Major Influence on Government Vaccine Policy
    http://vaccineresistancemovement.org/?p=1880

    VRM: Closed Door CDC Meeting Reveals Industry Cover-up Of Heavy Metal Toxicity In Vaccines
    http://vaccineresistancemovement.org/?p=5935

    VRM: The Rockefeller Foundation Drafts A Post-Pandemic Scenario
    http://vaccineresistancemovement.org/?p=5102

    VRM : World Health Organization & Vaccine Manufacturers Implicated In Massive H1N1 Financial Scam Involving Kickbacks & Cover-ups
    http://vaccineresistancemovement.org/?p=4610

    VRM : Former Pharmaceutical Representative Gwen Olsen Exposes Systemic Industry Fraud
    http://vaccineresistancemovement.org/?p=5920

    VRM: Britain’s National Health Service – Criminal Syndicate Swindling Billions While Rapidly Destroying Health Care System
    http://vaccineresistancemovement.org/?p=4986

    VRM: UK Institutes Brand of Medical Martial Law With ‘Super-Vaccination’ Day
    http://vaccineresistancemovement.org/?p=4986

    VRM : The Awakening Has Begun
    http://vaccineresistancemovement.org/?p=6469

    VRM: Medical Martial Law In The US – Sleeping Giant Of Tyranny
    http://vaccineresistancemovement.org/?p=5865

    VRM : Multi-Virus Vaccine Quinvaxem Proving Deadly
    http://vaccineresistancemovement.org/?p=5219

    VRM: New Generation Cancer Vaccine Will Cause Infertility
    http://vaccineresistancemovement.org/?p=5311

    VRM: CDC-Gate Exposes A Trail of Fraud Behind Autism Studies
    http://vaccineresistancemovement.org/?p=5743

    VRM : Squaline – The Military Agenda Comes Home
    http://vaccineresistancemovement.org/?p=1797

    VRM Live – 01/28/11: Vaccine Resistance Movement founder Joel Lord discusses Synthetic Genomics, cloned cell vaccine technology & the death of natural immunity, gutter journalism & Dr. Wakefield’s imminent vindication with ‘Truth to Power’ host Paul Mabelis.
    http://www.blogtalkradio.com/empradio/2011/01/28/truth-to-power-thursday

    VRM Live – 11/04/10: Vaccine Resistance Movement founder Joel Lord lays out the whole vaccine process with Paul Mabelis; including heavy metal toxicity, synergy, pregnancy issues & the basic principles of natural health at risk.
    http://www.blogtalkradio.com/show.aspx?userurl=empradio&year=2010&month=11&day=05&url=truth-to-power-thursday

    VRM Live – 09/24/10: Vaccine Resistance Movement Founder Joel Lord & activist/radio host Jesse Calhoun lay it all out tonite. Topics include the VRM Worldwide Autism Study, Scientific/Medical dictatorship, Natural Rights & Vaccine Industry fraud exposed. Special thanks to host Paul Mabelis.
    http://www.blogtalkradio.com/empradio/2010/09/24/truth-to-power-thursday

    If you appreciate the efforts to bring this information forward do consider making a donation. Any amount, no matter how small will help enable me to carry on this invaluable research. See Paypal link on the VRM website (click on ‘Donate’ tab in upper right corner). Thank you all.

    logo.VRM_Ver.2.1

  • 5 Responses to “VRM: Former Pharmaceutical Representative Gwen Olsen Exposes Systemic Industry Fraud”


<ul><li><strong>woo_cat_nav_107</strong> - false</li><li><strong>woo_cat_nav_141</strong> - false</li><li><strong>woo_cat_nav_142</strong> - false</li><li><strong>woo_cat_nav_126</strong> - false</li><li><strong>woo_cat_nav_177</strong> - false</li><li><strong>woo_cat_nav_138</strong> - false</li><li><strong>woo_cat_nav_109</strong> - false</li><li><strong>woo_cat_nav_172</strong> - false</li><li><strong>woo_cat_nav_169</strong> - false</li><li><strong>woo_cat_nav_160</strong> - false</li><li><strong>woo_cat_nav_131</strong> - false</li><li><strong>woo_cat_nav_162</strong> - false</li><li><strong>woo_cat_nav_137</strong> - false</li><li><strong>woo_cat_nav_174</strong> - false</li><li><strong>woo_cat_nav_171</strong> - false</li><li><strong>woo_cat_nav_144</strong> - false</li><li><strong>woo_cat_nav_173</strong> - false</li><li><strong>woo_cat_nav_136</strong> - false</li><li><strong>woo_cat_nav_178</strong> - false</li><li><strong>woo_cat_nav_165</strong> - false</li><li><strong>woo_cat_nav_106</strong> - false</li><li><strong>woo_cat_nav_127</strong> - false</li><li><strong>woo_cat_nav_176</strong> - false</li><li><strong>woo_cat_nav_135</strong> - false</li><li><strong>woo_cat_nav_175</strong> - false</li><li><strong>woo_cat_color_107</strong> - </li><li><strong>woo_cat_color_141</strong> - </li><li><strong>woo_cat_color_142</strong> - </li><li><strong>woo_cat_color_126</strong> - </li><li><strong>woo_cat_color_177</strong> - </li><li><strong>woo_cat_color_138</strong> - </li><li><strong>woo_cat_color_109</strong> - </li><li><strong>woo_cat_color_172</strong> - </li><li><strong>woo_cat_color_169</strong> - </li><li><strong>woo_cat_color_160</strong> - </li><li><strong>woo_cat_color_131</strong> - </li><li><strong>woo_cat_color_162</strong> - </li><li><strong>woo_cat_color_137</strong> - </li><li><strong>woo_cat_color_174</strong> - </li><li><strong>woo_cat_color_171</strong> - </li><li><strong>woo_cat_color_144</strong> - </li><li><strong>woo_cat_color_173</strong> - </li><li><strong>woo_cat_color_136</strong> - </li><li><strong>woo_cat_color_178</strong> - </li><li><strong>woo_cat_color_165</strong> - </li><li><strong>woo_cat_color_106</strong> - </li><li><strong>woo_cat_color_127</strong> - </li><li><strong>woo_cat_color_176</strong> - </li><li><strong>woo_cat_color_135</strong> - </li><li><strong>woo_cat_color_175</strong> - </li><li><strong>woo_cat_nav_59</strong> - true</li><li><strong>woo_cat_nav_64</strong> - true</li><li><strong>woo_cat_nav_65</strong> - true</li><li><strong>woo_cat_nav_70</strong> - true</li><li><strong>woo_cat_nav_66</strong> - false</li><li><strong>woo_cat_nav_60</strong> - false</li><li><strong>woo_cat_nav_62</strong> - true</li><li><strong>woo_cat_nav_71</strong> - true</li><li><strong>woo_cat_nav_63</strong> - false</li><li><strong>woo_cat_nav_67</strong> - true</li><li><strong>woo_cat_nav_68</strong> - false</li><li><strong>woo_cat_nav_69</strong> - true</li><li><strong>woo_cat_nav_61</strong> - true</li><li><strong>woo_cat_color_59</strong> - </li><li><strong>woo_cat_color_64</strong> - </li><li><strong>woo_cat_color_65</strong> - </li><li><strong>woo_cat_color_70</strong> - </li><li><strong>woo_cat_color_66</strong> - </li><li><strong>woo_cat_color_60</strong> - </li><li><strong>woo_cat_color_62</strong> - </li><li><strong>woo_cat_color_71</strong> - </li><li><strong>woo_cat_color_63</strong> - </li><li><strong>woo_cat_color_67</strong> - </li><li><strong>woo_cat_color_68</strong> - </li><li><strong>woo_cat_color_69</strong> - </li><li><strong>woo_cat_color_61</strong> - </li><li><strong>woo_cat_nav_81</strong> - true</li><li><strong>woo_cat_nav_82</strong> - true</li><li><strong>woo_cat_nav_83</strong> - true</li><li><strong>woo_post_size</strong> - false</li><li><strong>woo_themename</strong> - myweblog</li><li><strong>woo_shortname</strong> - woo</li><li><strong>woo_manual</strong> - http://www.woothemes.com/support/theme-documentation/wootheme/</li><li><strong>woo_single_thumb</strong> - true</li><li><strong>woo_alt_stylesheet</strong> - default.css</li><li><strong>woo_logo</strong> - </li><li><strong>woo_custom_favicon</strong> - </li><li><strong>woo_google_analytics</strong> - <script type=\"text/javascript\">
var gaJsHost = ((\"https:\" == document.location.protocol) ? \"https://ssl.\" : \"http://www.\");
document.write(unescape(\"%3Cscript src=\'\" + gaJsHost + \"google-analytics.com/ga.js\' type=\'text/javascript\'%3E%3C/script%3E\"));
</script>
<script type=\"text/javascript\">
try {
var pageTracker = _gat._getTracker(\"UA-13204227-1\");
pageTracker._trackPageview();
} catch(err) {}</script></li><li><strong>woo_feedburner_url</strong> - </li><li><strong>woo_custom_css</strong> - </li><li><strong>woo_resize</strong> - false</li><li><strong>woo_auto_img</strong> - false</li><li><strong>woo_cat_nav_3</strong> - true</li><li><strong>woo_cat_nav_1</strong> - true</li><li><strong>woo_cat_color_3</strong> - </li><li><strong>woo_cat_color_1</strong> - </li><li><strong>woo_ad_footer</strong> - false</li><li><strong>woo_ad_footer_adsense</strong> - </li><li><strong>woo_ad_footer_image</strong> - http://vaccineresistancemovement.org/wp-content/woo_uploads/4-3-banner-oxysilver.jpg</li><li><strong>woo_ad_footer_url</strong> - http://www.woothemes.com</li><li><strong>woo_sidebar_ad_img_1</strong> - http://www.woothemes.com/ads/woothemes-125x125-1.gif</li><li><strong>woo_sidebar_ad_href_1</strong> - http://www.woothemes.com</li><li><strong>woo_sidebar_ad_img_2</strong> - http://www.woothemes.com/ads/woothemes-125x125-2.gif</li><li><strong>woo_sidebar_ad_href_2</strong> - http://www.woothemes.com</li><li><strong>woo_sidebar_ad_img_3</strong> - http://www.woothemes.com/ads/woothemes-125x125-3.gif</li><li><strong>woo_sidebar_ad_href_3</strong> - http://www.woothemes.com</li><li><strong>woo_sidebar_ad_img_4</strong> - http://www.woothemes.com/ads/woothemes-125x125-4.gif</li><li><strong>woo_sidebar_ad_href_4</strong> - http://www.woothemes.com</li><li><strong>woo_cat_nav_55</strong> - true</li><li><strong>woo_cat_nav_49</strong> - true</li><li><strong>woo_cat_nav_41</strong> - true</li><li><strong>woo_cat_nav_39</strong> - true</li><li><strong>woo_cat_color_46</strong> - </li><li><strong>woo_cat_color_40</strong> - </li><li><strong>woo_cat_color_42</strong> - </li><li><strong>woo_cat_color_51</strong> - </li><li><strong>woo_cat_color_35</strong> - </li><li><strong>woo_cat_color_32</strong> - </li><li><strong>woo_cat_color_37</strong> - </li><li><strong>woo_cat_color_38</strong> - </li><li><strong>woo_cat_color_52</strong> - </li><li><strong>woo_cat_color_50</strong> - </li><li><strong>woo_cat_color_49</strong> - </li><li><strong>woo_cat_color_41</strong> - </li><li><strong>woo_cat_color_39</strong> - </li><li><strong>woo_cat_nav_23</strong> - true</li><li><strong>woo_cat_nav_4</strong> - false</li><li><strong>woo_cat_nav_28</strong> - false</li><li><strong>woo_cat_nav_5</strong> - true</li><li><strong>woo_cat_nav_27</strong> - true</li><li><strong>woo_cat_nav_6</strong> - true</li><li><strong>woo_cat_nav_7</strong> - true</li><li><strong>woo_cat_nav_24</strong> - false</li><li><strong>woo_cat_nav_8</strong> - true</li><li><strong>woo_cat_nav_9</strong> - true</li><li><strong>woo_cat_nav_10</strong> - true</li><li><strong>woo_cat_nav_11</strong> - true</li><li><strong>woo_cat_nav_30</strong> - true</li><li><strong>woo_cat_nav_12</strong> - true</li><li><strong>woo_cat_nav_25</strong> - true</li><li><strong>woo_cat_nav_13</strong> - true</li><li><strong>woo_cat_nav_14</strong> - true</li><li><strong>woo_cat_nav_15</strong> - true</li><li><strong>woo_cat_nav_26</strong> - true</li><li><strong>woo_cat_nav_16</strong> - false</li><li><strong>woo_cat_nav_17</strong> - true</li><li><strong>woo_cat_nav_29</strong> - true</li><li><strong>woo_cat_nav_18</strong> - true</li><li><strong>woo_cat_nav_19</strong> - true</li><li><strong>woo_cat_nav_20</strong> - false</li><li><strong>woo_cat_nav_21</strong> - true</li><li><strong>woo_cat_nav_22</strong> - true</li><li><strong>woo_cat_nav_31</strong> - true</li><li><strong>woo_cat_color_23</strong> - </li><li><strong>woo_cat_color_4</strong> - </li><li><strong>woo_cat_color_28</strong> - 03246B</li><li><strong>woo_cat_color_5</strong> - </li><li><strong>woo_cat_color_27</strong> - </li><li><strong>woo_cat_color_6</strong> - </li><li><strong>woo_cat_color_7</strong> - </li><li><strong>woo_cat_color_24</strong> - </li><li><strong>woo_cat_color_8</strong> - </li><li><strong>woo_cat_color_9</strong> - </li><li><strong>woo_cat_color_10</strong> - </li><li><strong>woo_cat_color_11</strong> - </li><li><strong>woo_cat_color_30</strong> - </li><li><strong>woo_cat_color_12</strong> - </li><li><strong>woo_cat_color_25</strong> - </li><li><strong>woo_cat_color_13</strong> - </li><li><strong>woo_cat_color_14</strong> - </li><li><strong>woo_cat_color_15</strong> - </li><li><strong>woo_cat_color_26</strong> - </li><li><strong>woo_cat_color_16</strong> - </li><li><strong>woo_cat_color_17</strong> - </li><li><strong>woo_cat_color_29</strong> - </li><li><strong>woo_cat_color_18</strong> - </li><li><strong>woo_cat_color_19</strong> - </li><li><strong>woo_cat_color_20</strong> - </li><li><strong>woo_cat_color_21</strong> - </li><li><strong>woo_cat_color_22</strong> - </li><li><strong>woo_cat_color_31</strong> - </li><li><strong>woo_cat_nav_233</strong> - false</li><li><strong>woo_cat_nav_222</strong> - false</li><li><strong>woo_cat_nav_46</strong> - false</li><li><strong>woo_cat_nav_40</strong> - true</li><li><strong>woo_cat_nav_42</strong> - true</li><li><strong>woo_cat_nav_51</strong> - true</li><li><strong>woo_cat_nav_35</strong> - true</li><li><strong>woo_cat_nav_32</strong> - true</li><li><strong>woo_cat_nav_37</strong> - true</li><li><strong>woo_cat_nav_38</strong> - true</li><li><strong>woo_cat_nav_52</strong> - true</li><li><strong>woo_cat_nav_50</strong> - false</li><li><strong>woo_cat_nav_53</strong> - true</li><li><strong>woo_cat_nav_54</strong> - true</li><li><strong>woo_cat_nav_56</strong> - true</li><li><strong>woo_cat_nav_57</strong> - true</li><li><strong>woo_cat_color_55</strong> - </li><li><strong>woo_cat_color_53</strong> - </li><li><strong>woo_cat_color_54</strong> - </li><li><strong>woo_cat_color_56</strong> - </li><li><strong>woo_cat_color_57</strong> - </li><li><strong>woo_uploads</strong> - a:2:{i:0;s:84:"http://vaccineresistancemovement.org/wp-content/woo_uploads/4-3-banner-oxysilver.jpg";i:1;s:82:"http://vaccineresistancemovement.org/wp-content/woo_uploads/3-banner-oxysilver.jpg";}</li><li><strong>woo_cat_nav_58</strong> - false</li><li><strong>woo_cat_color_58</strong> - </li><li><strong>woo_cat_nav_80</strong> - true</li><li><strong>woo_cat_nav_78</strong> - true</li><li><strong>woo_cat_nav_73</strong> - true</li><li><strong>woo_cat_nav_74</strong> - true</li><li><strong>woo_cat_nav_72</strong> - true</li><li><strong>woo_cat_nav_79</strong> - true</li><li><strong>woo_cat_nav_76</strong> - true</li><li><strong>woo_cat_nav_75</strong> - true</li><li><strong>woo_cat_nav_77</strong> - true</li><li><strong>woo_cat_color_81</strong> - </li><li><strong>woo_cat_color_82</strong> - </li><li><strong>woo_cat_color_83</strong> - </li><li><strong>woo_cat_color_80</strong> - </li><li><strong>woo_cat_color_78</strong> - </li><li><strong>woo_cat_color_73</strong> - </li><li><strong>woo_cat_color_74</strong> - </li><li><strong>woo_cat_color_72</strong> - </li><li><strong>woo_cat_color_79</strong> - 2F83DE</li><li><strong>woo_cat_color_76</strong> - </li><li><strong>woo_cat_color_75</strong> - </li><li><strong>woo_cat_color_77</strong> - </li><li><strong>woo_cat_nav_98</strong> - true</li><li><strong>woo_cat_nav_104</strong> - true</li><li><strong>woo_cat_nav_99</strong> - true</li><li><strong>woo_cat_nav_101</strong> - true</li><li><strong>woo_cat_nav_95</strong> - true</li><li><strong>woo_cat_nav_102</strong> - true</li><li><strong>woo_cat_nav_105</strong> - true</li><li><strong>woo_cat_nav_100</strong> - false</li><li><strong>woo_cat_nav_103</strong> - true</li><li><strong>woo_cat_nav_96</strong> - true</li><li><strong>woo_cat_nav_97</strong> - true</li><li><strong>woo_cat_nav_85</strong> - true</li><li><strong>woo_cat_nav_91</strong> - true</li><li><strong>woo_cat_nav_93</strong> - true</li><li><strong>woo_cat_nav_92</strong> - true</li><li><strong>woo_cat_nav_89</strong> - true</li><li><strong>woo_cat_nav_90</strong> - true</li><li><strong>woo_cat_nav_88</strong> - true</li><li><strong>woo_cat_nav_87</strong> - true</li><li><strong>woo_cat_nav_94</strong> - true</li><li><strong>woo_cat_nav_86</strong> - true</li><li><strong>woo_cat_nav_84</strong> - false</li><li><strong>woo_cat_color_98</strong> - </li><li><strong>woo_cat_color_104</strong> - </li><li><strong>woo_cat_color_99</strong> - </li><li><strong>woo_cat_color_101</strong> - </li><li><strong>woo_cat_color_95</strong> - </li><li><strong>woo_cat_color_102</strong> - </li><li><strong>woo_cat_color_105</strong> - </li><li><strong>woo_cat_color_100</strong> - </li><li><strong>woo_cat_color_103</strong> - </li><li><strong>woo_cat_color_96</strong> - </li><li><strong>woo_cat_color_97</strong> - </li><li><strong>woo_cat_color_85</strong> - </li><li><strong>woo_cat_color_91</strong> - </li><li><strong>woo_cat_color_93</strong> - </li><li><strong>woo_cat_color_92</strong> - </li><li><strong>woo_cat_color_89</strong> - </li><li><strong>woo_cat_color_90</strong> - </li><li><strong>woo_cat_color_88</strong> - </li><li><strong>woo_cat_color_87</strong> - </li><li><strong>woo_cat_color_94</strong> - </li><li><strong>woo_cat_color_86</strong> - </li><li><strong>woo_cat_color_84</strong> - </li><li><strong>woo_cat_nav_219</strong> - false</li><li><strong>woo_cat_nav_230</strong> - false</li><li><strong>woo_cat_nav_192</strong> - false</li><li><strong>woo_cat_nav_224</strong> - false</li><li><strong>woo_cat_nav_215</strong> - false</li><li><strong>woo_cat_nav_193</strong> - false</li><li><strong>woo_cat_nav_202</strong> - false</li><li><strong>woo_cat_nav_211</strong> - false</li><li><strong>woo_cat_nav_235</strong> - false</li><li><strong>woo_cat_nav_208</strong> - false</li><li><strong>woo_cat_nav_209</strong> - false</li><li><strong>woo_cat_nav_204</strong> - false</li><li><strong>woo_cat_nav_180</strong> - false</li><li><strong>woo_cat_nav_200</strong> - false</li><li><strong>woo_cat_nav_186</strong> - false</li><li><strong>woo_cat_nav_187</strong> - false</li><li><strong>woo_cat_nav_190</strong> - false</li><li><strong>woo_cat_nav_205</strong> - false</li><li><strong>woo_cat_nav_229</strong> - false</li><li><strong>woo_cat_nav_197</strong> - false</li><li><strong>woo_cat_nav_189</strong> - false</li><li><strong>woo_cat_nav_206</strong> - false</li><li><strong>woo_cat_nav_212</strong> - false</li><li><strong>woo_cat_nav_213</strong> - false</li><li><strong>woo_cat_nav_214</strong> - false</li><li><strong>woo_cat_nav_218</strong> - false</li><li><strong>woo_cat_nav_226</strong> - false</li><li><strong>woo_cat_nav_181</strong> - false</li><li><strong>woo_cat_nav_196</strong> - false</li><li><strong>woo_cat_nav_184</strong> - false</li><li><strong>woo_cat_nav_194</strong> - false</li><li><strong>woo_cat_nav_234</strong> - false</li><li><strong>woo_cat_nav_228</strong> - false</li><li><strong>woo_cat_nav_221</strong> - false</li><li><strong>woo_cat_nav_220</strong> - false</li><li><strong>woo_cat_color_235</strong> - </li><li><strong>woo_cat_color_208</strong> - </li><li><strong>woo_cat_color_209</strong> - </li><li><strong>woo_cat_color_204</strong> - </li><li><strong>woo_cat_color_180</strong> - </li><li><strong>woo_cat_color_200</strong> - </li><li><strong>woo_cat_color_186</strong> - </li><li><strong>woo_cat_color_187</strong> - </li><li><strong>woo_cat_color_190</strong> - </li><li><strong>woo_cat_color_205</strong> - </li><li><strong>woo_cat_color_229</strong> - </li><li><strong>woo_cat_color_197</strong> - </li><li><strong>woo_cat_color_189</strong> - </li><li><strong>woo_cat_color_206</strong> - </li><li><strong>woo_cat_color_210</strong> - </li><li><strong>woo_cat_color_231</strong> - </li><li><strong>woo_cat_color_191</strong> - </li><li><strong>woo_cat_color_201</strong> - </li><li><strong>woo_cat_color_179</strong> - </li><li><strong>woo_cat_color_198</strong> - </li><li><strong>woo_cat_color_199</strong> - </li><li><strong>woo_cat_color_207</strong> - </li><li><strong>woo_cat_color_223</strong> - </li><li><strong>woo_cat_color_227</strong> - </li><li><strong>woo_cat_color_203</strong> - </li><li><strong>woo_cat_color_188</strong> - </li><li><strong>woo_cat_color_183</strong> - </li><li><strong>woo_cat_color_232</strong> - </li><li><strong>woo_cat_color_185</strong> - </li><li><strong>woo_cat_color_217</strong> - </li><li><strong>woo_cat_color_216</strong> - </li><li><strong>woo_cat_color_225</strong> - </li><li><strong>woo_cat_color_233</strong> - </li><li><strong>woo_cat_color_222</strong> - </li><li><strong>woo_cat_color_219</strong> - </li><li><strong>woo_cat_color_230</strong> - </li><li><strong>woo_cat_color_192</strong> - </li><li><strong>woo_cat_color_224</strong> - </li><li><strong>woo_cat_color_215</strong> - </li><li><strong>woo_cat_color_193</strong> - </li><li><strong>woo_cat_color_202</strong> - </li><li><strong>woo_cat_color_211</strong> - </li><li><strong>woo_cat_color_212</strong> - </li><li><strong>woo_cat_color_213</strong> - </li><li><strong>woo_cat_color_214</strong> - </li><li><strong>woo_cat_color_218</strong> - </li><li><strong>woo_cat_color_226</strong> - </li><li><strong>woo_cat_color_181</strong> - </li><li><strong>woo_cat_color_196</strong> - </li><li><strong>woo_cat_color_184</strong> - </li><li><strong>woo_cat_color_194</strong> - </li><li><strong>woo_cat_color_234</strong> - </li><li><strong>woo_cat_color_228</strong> - </li><li><strong>woo_cat_color_221</strong> - </li><li><strong>woo_cat_color_220</strong> - </li><li><strong>woo_cat_nav_210</strong> - false</li><li><strong>woo_cat_nav_231</strong> - false</li><li><strong>woo_cat_nav_191</strong> - false</li><li><strong>woo_cat_nav_201</strong> - false</li><li><strong>woo_cat_nav_179</strong> - false</li><li><strong>woo_cat_nav_198</strong> - false</li><li><strong>woo_cat_nav_199</strong> - false</li><li><strong>woo_cat_nav_207</strong> - false</li><li><strong>woo_cat_nav_223</strong> - false</li><li><strong>woo_cat_nav_227</strong> - false</li><li><strong>woo_cat_nav_203</strong> - false</li><li><strong>woo_cat_nav_188</strong> - false</li><li><strong>woo_cat_nav_183</strong> - false</li><li><strong>woo_cat_nav_232</strong> - false</li><li><strong>woo_cat_nav_185</strong> - false</li><li><strong>woo_cat_nav_217</strong> - false</li><li><strong>woo_cat_nav_216</strong> - false</li><li><strong>woo_cat_nav_225</strong> - false</li></ul>